^
Association details:
| Biomarker: | BRCA1 deletion |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | PLX038 (Topoisomerase I inhibitor, DDR enhancer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors
Published date:
11/03/2022
Excerpt:
PLX038 monotherapy and combination with PARP inhibition potently inhibited the growth of both BRCA1- and ATM-deficient tumors. A patient with an ATM-mutated breast cancer treated with PLX038 and the PARP inhibitor rucaparib achieved rapid, symptomatic, and radiographic complete response lasting 12 months.
DOI:
10.1158/1535-7163.MCT-22-0217
Source:
Title:
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors
Published date:
11/03/2022
Excerpt:
PLX038 monotherapy and combination with PARP inhibition potently inhibited the growth of both BRCA1- and ATM-deficient tumors. A patient with an ATM-mutated breast cancer treated with PLX038 and the PARP inhibitor rucaparib achieved rapid, symptomatic, and radiographic complete response lasting 12 months.
Secondary therapy:
PARP inhibitors
DOI:
10.1158/1535-7163.MCT-22-0217
